- $11.45bn
- $16.05bn
- $4.38bn
Novo Nordisk rises as Catalent deal in US nears
Regulatory conditions on Novo Holdings' $16.5 bln Catalent deal fulfilled, companies say
Brief: Catalent And Novo Holdings Fulfill All Regulatory Closing Conditions For Pending Transaction
Brief: Novo Nordisk Says All Regulatory Closing Conditions Relating To Review Of Novo Holdings A/S's Pending Acquisition Of Catalent Have Been Fulfilled
Deals of the day-Mergers and acquisitions
Novo Holdings' $16.5 bln Catalent buy wins EU antitrust approval (updated)
Novo Holdings' $16.5 bln Catalent buy wins EU antitrust approval
European pharma’s growth prescription: pivot to US
European pharma’s growth prescription: pivot to US
Novo Holdings set to win EU nod for $16.5 bln Catalent deal, source says (updated)
EU antitrust regulators set to okay $16.5 bln Novo Holdings, Catalent deal, source says
Barclays sees challenging outlook for EU pharma in 2025, prefers Novo and AstraZeneca
EU regulators quiz Novo Nordisk, Catalent rivals on $16.5 bln deal
Catalent misses Q1 revenue estimates ahead of $16.5 bln deal close with Novo Holdings
Brief: Catalent Q1 Revenue USD 1,020 Million Vs. IBES Estimate USD 1,058 Million
EU antitrust regulators to rule on Novo's Catalent buy by Dec. 6 (updated)
EU antitrust regulators to decide on Novo's Catalent buy by Dec. 6
Sanofi CFO says won't be affected by Novo's Catalent deal
Roche comes out against clearing takeover of drug manufacturer Catalent (updated)